Growth Factor Receptor Targeting

Drummond DC, Marx C, Guo Z, et al. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res 2005 11 3392-3401. Mamot C, Drummond Dc, Noble CO, et al. Epledermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugsin vivo. Cancer Res 2005 65 1631-1638. 

Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol... 

Mamot C et al (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65 11631-11638... 

P. Magadala, M. Amiji, Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells, AAPS Journal 10 (2008) 565-576. 

Epidermal Growth Factor Receptor-Targeted Liposomes... 

Soukos, N.S., Hambhn, M.R., Keel, S., Fabian, RL., Deutsch, T.F., and Hasan, T, Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in... 

The epidermal growth factor receptor 2 (HER-2) is a protein found on the surface of cells. Heterodimerization of HER-2 activates the enzyme tyrosine kinase, triggering reactions that cause the cells to grow and multiply. HER-2 is found at abnormally high levels on the surface of many types of cancer cells, which may divide excessively. Antibodies targeting HER-2 (e.g., trastuzumab) are used as antineoplastic agents. 

More recently attempts to generate highly selective quiescent affinity labels have been made for a number of protease and kinase targets. As examples, inhibitors of the Rhinovirus 3C protease (Mathews et al 1999) and of the epidermal growth factor receptors (Boschelli, 2002), both incorporating Michael acceptors to covalently inactivate cysteine residues in their target enzymes (Lowry and Richardson, 1981 Figure 8.6), have entered human clinical trials for the treatment of rhinovirus infection and cancer, respectively. 

Bergmann F, Breinig M, Hopfner M, et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2 novel chemotherapeutic targets in pancreatic endocrine tumors. Am. J. Gastroenterol. 2009 104 171-181. 

Board, R. and Jayson, G. 2005. Platelet-derived growth factor receptor (PDGFR) a target for anti cancer therapeutics. Drug Resistance Updates 8(1-2), 75-83. 

Johnstone, P. 2002. The epidermal growth factor receptor a new target for anticancer therapy - introduction. Current Problems in Cancer 26(3), 114-164. 

Kane, S. 2006. Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents 16(2), 147-164. 

Lapatinib, a tyrosine kinase inhibitor that targets both HER2 and the epidermal growth factor receptor, improved response rates and time to progression in combination with capecitabine, as compared to capecitabine alone, in patients previously treated with an anthracycline, taxane, and trastuzumab. The most common adverse events were rash and diarrhea. 

---